Clinical Trial

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

Recruiting
View on ClinicalTrials.gov →
Summary
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.
Protocol Amendment History 1 change
critical Recruitment suspended 2026-04-04
Trial Details
NCT Number NCT07285668
Lead Sponsor University of Wisconsin, Madison
Conditions Hematologic Malignancies
Enrollment 38 participants
Start Date 2026-02-26
Primary Completion 2029-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-24